Imperial College London
Portrait Picture

ProfessorDannyAltmann

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Immunology
 
 
 
//

Contact

 

+44 (0)20 3313 8212d.altmann

 
 
//

Location

 

5S5CHammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Alexander:2022:10.1016/S2468-1253(22)00005-X,
author = {Alexander, JL and Kennedy, NA and Ibraheim, H and Anandabaskaran, S and Saifuddin, A and Castro, Seoane R and Liu, Z and Nice, R and Bewshea, C and D'Mello, A and Constable, L and Jones, GR and Balarajah, S and Fiorentino, F and Sebastian, S and Irving, PM and Hicks, LC and Williams, HRT and Kent, AJ and Linger, R and Parkes, M and Kok, K and Patel, KV and Teare, JP and Altmann, DM and Boyton, RJ and Goodhand, JR and Hart, AL and Lees, CW and Ahmad, T and Powell, N and VIP, study investigators},
doi = {10.1016/S2468-1253(22)00005-X},
journal = {The Lancet Gastroenterology & Hepatology},
pages = {342--352},
title = {COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study},
url = {http://dx.doi.org/10.1016/S2468-1253(22)00005-X},
volume = {7},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: The effects that therapies for inflammatory bowel disease (IBD) have on immune responses to SARS-CoV-2 vaccination are not yet fully known. Therefore, we sought to determine whether COVID-19 vaccine-induced antibody responses were altered in patients with IBD on commonly used immunosuppressive drugs. METHODS: In this multicentre, prospective, case-control study (VIP), we recruited adults with IBD treated with one of six different immunosuppressive treatment regimens (thiopurines, infliximab, a thiopurine plus infliximab, ustekinumab, vedolizumab, or tofacitinib) and healthy control participants from nine centres in the UK. Eligible participants were aged 18 years or older and had received two doses of COVID-19 vaccines (either ChAdOx1 nCoV-19 [Oxford-AstraZeneca], BNT162b2 [Pfizer-BioNTech], or mRNA1273 [Moderna]) 6-12 weeks apart (according to scheduling adopted in the UK). We measured antibody responses 53-92 days after a second vaccine dose using the Roche Elecsys Anti-SARS-CoV-2 spike electrochemiluminescence immunoassay. The primary outcome was anti-SARS-CoV-2 spike protein antibody concentrations in participants without previous SARS-CoV-2 infection, adjusted by age and vaccine type, and was analysed by use of multivariable linear regression models. This study is registered in the ISRCTN Registry, ISRCTN13495664, and is ongoing. FINDINGS: Between May 31 and Nov 24, 2021, we recruited 483 participants, including patients with IBD being treated with thiopurines (n=78), infliximab (n=63), a thiopurine plus infliximab (n=72), ustekinumab (n=57), vedolizumab (n=62), or tofacitinib (n=30), and 121 healthy controls. We included 370 participants without evidence of previous infection in our primary analysis. Geometric mean anti-SARS-CoV-2 spike protein antibody concentrations were significantly lower in patients treated with infliximab (156·8 U/mL [geometric SD 5·7]; p<0·0001), infliximab plus thiopurine (111·1 U/mL [5·
AU  - Alexander,JL
AU  - Kennedy,NA
AU  - Ibraheim,H
AU  - Anandabaskaran,S
AU  - Saifuddin,A
AU  - Castro,Seoane R
AU  - Liu,Z
AU  - Nice,R
AU  - Bewshea,C
AU  - D'Mello,A
AU  - Constable,L
AU  - Jones,GR
AU  - Balarajah,S
AU  - Fiorentino,F
AU  - Sebastian,S
AU  - Irving,PM
AU  - Hicks,LC
AU  - Williams,HRT
AU  - Kent,AJ
AU  - Linger,R
AU  - Parkes,M
AU  - Kok,K
AU  - Patel,KV
AU  - Teare,JP
AU  - Altmann,DM
AU  - Boyton,RJ
AU  - Goodhand,JR
AU  - Hart,AL
AU  - Lees,CW
AU  - Ahmad,T
AU  - Powell,N
AU  - VIP,study investigators
DO  - 10.1016/S2468-1253(22)00005-X
EP  - 352
PY  - 2022///
SN  - 2468-1253
SP  - 342
TI  - COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
T2  - The Lancet Gastroenterology & Hepatology
UR  - http://dx.doi.org/10.1016/S2468-1253(22)00005-X
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35123676
UR  - https://www.sciencedirect.com/science/article/pii/S246812532200005X?via%3Dihub
UR  - http://hdl.handle.net/10044/1/95009
VL  - 7
ER  -
Download